Abstract Library

#1828 5-Fluorouracile Plus Dacarbazine in Metastatic Digestive Neuroendoendocrine Tumors: Efficacy and Potential Biomarkers

Introduction: The 5-fluorouracile (5FU) + dacarbazine (DTIC) combination has been poorly evaluated in NET

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: de Mestier L

Authors: De Mestier L, Cros J, Hentic O, Legoux J, Muller N,

Keywords: chemotherapy, tumor response, tolerance, pfs,

#1763 REMINET: A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors

Introduction: Patients (pts) with metastatic or locally advanced, non-resectable, grade 1 or 2 Well-differentiated duodeno-pancreatic (WDDP) NETs are treated following European guidelines. Pts with aggressive disease, i.e. progressive and/or symptomatic metastases and/or with significant hepatic invasion (> 30-50%), and/or bone metastases, anti-tumour therapy should receive systemic combination of chemotherapy once disease control is obtained.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lepage C

Authors: Lepage C, Dahan L, Legoux J, Le Malicot K, Guimbaud R,

Keywords: Duodeno-pancreatic neuroendocrine tumours, clinical trial, maintenance,